4519 Share Price Performance
JP¥0
-7130.00 (-100.00%)
Price JP¥0
Fair ValueJP¥8,171.43
Share Pricen/a
Chugai Pharmaceutical (TSE:4519) Has Announced A Dividend Of ¥125.00
Oct 29
Chugai Pharmaceutical Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
4519 Community Narratives
AN
Fair Value JP¥8.17k 0.7% undervalued intrinsic discount
Roche Collaboration And Biologics Pipeline Will Expand Healthcare Reach
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value JP¥10.73k 24.4% undervalued intrinsic discount
Aging Populations And Precision Medicine Will Expand Biologics Access
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value JP¥6.1k 33.0% overvalued intrinsic discount
Global Pricing Cuts And Pipeline Delays Will Dim Prospects
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Roche Collaboration And Biologics Pipeline Will Expand Healthcare Reach
Key Takeaways Focus on biologics, personalized medicine, and R&D productivity positions Chugai well for future growth and expansion of high-value therapies. Strategic partnerships, supply chain investments, and innovation improve global reach, production efficiency, and profit potential.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
JP¥8.17k
0.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
5.41% p.a.
Profit Margin
37.84%
Future PE
29.13x
Share price in 2028
JP¥9.38k
Aging Populations And Precision Medicine Will Expand Biologics Access
Key Takeaways Robust drug pipeline management and advanced manufacturing scale position Chugai to outpace rivals in innovation, output, and profitability as global biologic demand rises. Strategic investments in AI-driven discovery and portfolio focus enhance R&D productivity, enabling strong market leadership in next-generation, high-margin therapies.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
JP¥10.73k
24.4% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
10.05% p.a.
Profit Margin
40.79%
Future PE
31.18x
Share price in 2028
JP¥12.32k
Global Pricing Cuts And Pipeline Delays Will Dim Prospects
Key Takeaways Reliance on a narrow set of high-earning drugs and pipeline uncertainty increases exposure to competitive threats and potential revenue volatility. Ongoing price pressures, biosimilar competition, and major capital investments risk squeezing margins, straining cash flow, and impacting long-term growth prospects.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
JP¥6.1k
33.0% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
1.3% p.a.
Profit Margin
34.47%
Future PE
26.9x
Share price in 2028
JP¥7k
Snowflake Analysis
Chugai Pharmaceutical Co., Ltd. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Jan 29, 2026
- 241.33
- 69.48%
- 32.72%
- 0%
About 4519
- Founded
- 1925
- Employees
- 5026
- CEO
- WebsiteView website
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.